Zydus Cadila receives final approval from the USFDA to market Midodrine Hydrochloride Tablets

Zydus Cadila received final approval from the USFDA to market Midodrine Hydrochloride Tablets (US RLD- ProAmatine Tablets) in the strengths of 2.5 mg, 5 mg, and 10 mg.

The drug is used for certain patients who have symptoms of low blood pressure when standing. This condition is also known as orthostatic hypotension. The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.

The group now has 298 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.381.95 as compared to the previous close of Rs. 378.15. The total number of shares traded during the day was 155058 in over 2718 trades.

The stock hit an intraday high of Rs. 383.7 and intraday low of 373.5. The net turnover during the day was Rs. 58869902.

Source : Equity Bulls

Keywords